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After Coley’s observation in 1891 of tumor regression in a patient who developed a postop-
erative infection, the field of immunotherapy is finally reborn. Avoiding immune destruction 
is now considered a hallmark of cancer, and the immunotherapy arena has exploded with 
the recent advances demonstrating an improvement in survival and a durability of response 
in patients with different cancer types, which translates into improved overall survival 
benefit. Here, we provide an overview of the main immune-oncology treatment strategies 
that, either alone or in combination, are undergoing clinical development. Namely, we 
will refer to those immunotherapeutic strategies that include adoptive transfer of ex vivo 
activated T cells, immunomodulatory monoclonal antibodies, and cancer vaccines. Our 
major focus will be to describe these approaches in melanoma, a cancer type transformed 
by immunotherapy into a potentially curable disease.
Keywords: immunotherapy, melanoma, adoptive T cell therapy, immunomodulatory antibodies, vaccination, 
combination therapy
introduction
It was at the end of the nineteenth century when, following Coley’s observation of a spontaneous 
tumor regression due to postsurgical fever (1), the role played by immune system against cancer 
development came out of the shadow. Indeed, the longtime underestimated Coley’s observation has 
recently inspired the development of numerous anti-cancer immune approaches, which led to the 
rebirth of immunotherapy as epitomized by immunotherapy’s designation as the year breakthrough 
of 2013 by Science magazine (2). In the past 20 years, clinical and pathological observations have 
emphasized even more that the roles played by host immune cells in the tumor stroma are critical 
determinants of cancer biology and key factors for the success or failure of cancer therapy. Such 
discoveries have changed the field of tumor immunology so that “avoiding immune destruction” is 
now considered an emerging hallmark of cancer (3).
Although both innate (natural killer cells, macrophages, and dendritic cells) and adaptive T cell-
mediated immunity arms are postulated to play coordinated roles in cancer immune surveillance (4–6), 
most emphasis in immunotherapy has been placed on the adaptive immune response. In support of 
the critical role of T lymphocytes in human against cancer, tumor-infiltrating T lymphocyte cell (TIL) 
density estimated by tissue immunohistochemical (IHC) analysis has revealed a positive prognostic 
association between high density of CD8+ effector memory cells and overall survival (OS) of patients 
with melanoma and other cancer types (7, 8). Analysis conducted on pretreatment melanoma biopsies 
using gene expression analysis revealed that activation of interferon (IFN) signal transduction pathway 
signified by phosphorylated STAT1, IFNγ, CCR5 CXCR3, and their ligands are positively correlated 
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with favorable clinic outcome in breast cancer in terms of response 
to therapy (9). Furthermore, colon, ovary, melanoma, and breast 
cancer specimens have shown a positive correlation between up 
regulation of genes involved in the CD4+ Th1 adaptive immune 
response and a more favorable prognosis (5, 10).
To date, there is limited evidence with regard to the antigen 
specificity and understanding of the mechanisms of such spontane-
ous TIL cells. However, these observations have given rise to a 
conceptual model in which an adaptive T cell response composed 
of both cytotoxic CD8+ T cells (CTLs) and CD4+ Th1 cells con-
trol cancer progression. According to this immunosurveillance 
interpretation, the ability to produce cytokines, such as IFN-γ 
and tumor necrosis factor (TNF)-α, together with the expansion 
and activation of cytotoxic CD8+ T cells, is considered critical 
(11). Perhaps, because of these observations, attempts to exploit 
CTLs, TILs, and CD4+ Th1 cells have been the predominant 
immunotherapeutic approaches for cancer.
Here, we provide an overview of the most successful strategies 
in immunotherapy, used either as single agents or in synergistic 
treatment combinations. These include adoptive transfer of ex 
vivo activated T cells, immunomodulatory monoclonal antibodies 
(mAbs), and cancer vaccines. Challenges, advantages, and disad-
vantages associated with each of these approaches are discussed. 
Our major focus will be to describe these approaches in melanoma, 
a cancer type well known for its resistance to conventional radio 
and chemotherapy. However, since 2011, there have been consid-
erable advances in melanoma management with the approval of 
several treatments. In this context, the most encouraging results in 
stabilizing the disease and increasing the OS have been obtained 
by using immunotherapeutic approaches (12), which transformed 
the once unbeatable melanoma beast into a curable bet.
Adoptive T Cell Therapy
Adoptive cellular immunotherapy involves administering auto-
logous or allogeneic tumor-reactive T or NK cells to patients in 
order to achieve tumor regression. Today, adoptive T therapy 
represents one of the most promising therapies in the field of 
cancer treatment, showing extremely promising results in patients 
with B-cell leukemias lymphomas, and also in melanoma (13–15). 
Adoptive T cell therapy involves the isolation of lymphocytes with 
high affinity for tumor antigens, which can be selected ex vivo, 
stimulated, expanded, and infused back into the patient. The 
feasibility of generating T cells ex vivo is limited by the initial 
frequency of tumor antigen-specific T cells, which can be very 
low. Initially, tumor-specific T cells were selected from peripheral 
blood mononucleated cell (PBMCs) and cloned by limiting dilu-
tion in the presence of irradiated feeder cells. However, cultures of 
monoclonal and polyclonal T cells do show much efficiency neither 
in T cell expansion nor at inducing tumor rejection. The advance in 
tumor-specific T cells has been generated from enriched sources, 
such as TILs populations and tumor-draining lymph nodes. Before 
TIL infusions, patients must be heavily preconditioned by total 
body irradiation and lymphodepleting chemotherapy, which is 
supposed to eliminate both regulatory T cells and the competition 
for homeostatic cytokines, which sustain T-cell proliferation and 
survival. In melanoma, it has been shown that numerous tumor 
antigen-specific T cells can be isolated from excised material of 
a tumor mass, dissociating cells into single cell suspensions and 
adding the T-cell growth factor interleukin-2 (IL-2) (16). Several 
clinical trials using this approach have provided highly promising 
results, especially in melanoma. For instance, a series of studies 
collectively involving 93 patients with stage IV melanoma were 
treated with the adoptive transfer of autologous TILs administered 
in conjunction with IL-2 following a lymphodepleting preparative 
regimen on three clinical trials. Objective-response rates in the 
three trials using lymphodepleting preparative regimens (chemo-
therapy alone or with 2 or 12 Gy total body irradiation) were 49, 52, 
and 72%, respectively (15). Of particular note, 22% of patients had 
a complete tumor regression and most of these patients have been 
alive and disease-free for longer than 8 years (16). Encouraging 
results were also shown in another study by treating 57 patients 
with IV stage melanoma with unselected/young TIL and high-
dose IL-2 following non-myeloablative lymphodepletion. Overall 
response rates (ORR) were observed up to 40% with 23 patients 
achieving complete or partial remission (17).
Despite the successes of T adoptive therapy with TILs, a clinical 
response is still not guaranteed for all patients. Indeed, not all 
patients respond to this type of therapy in the same way and the 
reasons behind this differential response to TIL T cell transfer 
remain unknown. It has been shown that tumors escape TIL trans-
fer by several mechanisms and there is considerable evidence that 
TILs are blocked in vivo by many immunosuppressive molecules, 
such as programed cell death protein-1 (PD-1) and cytotoxic T 
cells antigen-4 (CTLA-4). Furthermore, increased expression of 
molecules with immunosuppressive properties, such as nitric-
oxide synthase 1 (NOS1) (18) or indoleamine 2,3-dioxygenase 
(IDO) might block TIL activity in tumors and decrease response 
to adoptive T cell transfer therapy (8). As such, a clear portrait of 
the phenomena associated with the lack of response observed in 
some patients is necessary in order to prevent both costly regimens 
and life-threatening side effects associated with the therapy.
As a consequence of the immune repertoire selection that 
takes place in immunosuppressive tumors in vivo, the affinity of 
the repertoire of endogenous T cell receptor (TCRs) for tumor-
specific antigens is suboptimal. Thus, several approaches have been 
developed to genetically engineer T cells with high affinity TCRs 
and thereby confer strong effector functions upon recognition of 
tumor-associated antigens. High avidity human TCRs are isolated 
either from in vitro cultures of naïve T cells with allogeneic peptide-
pulsed antigen-presenting cells (19) or following vaccination of 
humanized mice expressing transgenic human leukocyte antigen 
(HLA) alleles together with the human TCR alpha and beta loci 
mutated to avoid mispairing with the endogenous murine TCR 
chains (20). Candidate TCRs are sequenced, cloned, and inserted 
into retroviral or lentiviral vectors, which can be then used to trans-
duce autologous T cells from other patients with matching HLA 
restriction elements (21). The specificity of the TCR-transduced 
T cells is not altered compared to the parental T cell clone (22). 
Another problem associated with the transfer of genetically modi-
fied TCRs is that the recognition is restricted by a given HLA allele. 
This limitation is overcome by the use of chimeric antigen recep-
tors (CARs) in which a single-chain antibody (artificially linked 
light and heavy chains) is coupled to the transmembrane and 
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cytoplasmic signaling domains of the TCR complex (CD3-zeta) 
and co-stimulatory molecules (CD137 or CD28), that elicit lym-
phocyte activation upon antigen encounter. Due to the reduction 
of B cells numbers and B-cell aplasia following anti-CD19 CAR T 
cell treatment, this approach is taking the front seat of cancer treat-
ments especially in hematologic malignancies (14, 23). Genetic 
modification of T cells can also involve inserting genes to improve 
the efficacy of the T cells or induce co-stimulation and inhibit 
apoptosis of modified T cells. Risks associated with modifying T 
cells include the emergence of serious toxicity, such as cytokine 
release syndrome (16) or organ damage due to overexpression of 
the recognized antigen or cross-reactivity with other self-antigens. 
However, safety can be improved by identifying those antigens 
that can be targeted to destroy cancer cells without toxic effects 
in normal tissues and by gene transfer of drug-inducible suicide 
genes to abrogate toxicity.
Monoclonal Antibodies for 
Cancer Therapy
The use of mAbs in cancer therapy is one of the greatest clinical 
successes of the past decade. The fact that these antibodies can be 
used in the effective treatment of cancer is based on many years 
of comprehensive research into their complex structure, physical, 
chemical, and biological properties, specificity to targeted antigens, 
and therapeutic activity in vivo, either alone or in combination. 
Following the discovery of mABs by Cesar Miltein and George 
Kohler, their therapeutic use has relied on strategies to humanize 
their mouse sequences in such a way that their immune potential 
is much reduced when administered to humans.
In cancer therapy, an antibody can impact tumor regression 
through various mechanisms. First, direct action of the antibody 
on tumor cells through binding to a tumor cell surface receptor 
can induce receptor activation or an antagonist activity leading to 
tumor cell apoptosis. Second, the antibody may not act directly 
on the tumor but instead induce an immune response, which 
mediates tumor cell death by phagocytosis, complement activa-
tion [complement-dependent cytotoxicity (CDC)] or antibody-
dependent cellular cytotoxicity (ADCC). Third, the antibody may 
have a specific effect on the tumor stroma, such as toxin delivery to 
the stromal cell or the blockade of angiogenesis by an antagonizing 
vasculature receptor or growth factor (24).
In case of a direct effect or effect on tumor stroma, it is impor-
tant to consider that the efficacy of therapeutic mAbs is based 
on the target antigen, which, ideally, should be very abundant 
and specifically expressed on cancer cells or very selectively 
expressed in the tumor stroma. If possible, the antigen should 
be functionally related to the biology of cancer development 
and progression. In solid tumors, some of the most successful 
antibodies directly targeting tumor cells are those that block the 
ErbB family [which include epidermal growth factor receptor 
(EGFR) and human epidermal growth factor receptor 2 (HER2)] 
or vascular endothelial growth factor (VEGF). The anti HER2-
specific antibody, trastuzumab, was the first specific antibody to be 
clinically approved by federal drug administration (FDA) in 1998 
for the treatment of breast cancer HER2+ patients (25). In January 
2008, FDA approval for trastuzumab was revised to include its 
usage as stand-alone treatment (without chemotherapy) in 
the adjuvant setting. As with prior approval, trastuzumab was 
limited to patients with HER2-positive breast cancer but could 
be prescribed to patients regardless of lymph node involvement. 
Following trastuzumab approval, also additional mAbs have 
shown encouraging results in the treatment of solid tumors. 
In colon cancer, the EGFR-specific antibody cetuximab has 
been shown to improve response and survival in patients and 
has been now indicated as first line of treatment of metastatic 
disease in combination with chemotherapy (26). Also in breast 
cancer, studies evaluating the effect of cetuximab in combination 
with cisplatin showed an ORR of 20% (versus 10% for cisplatin 
alone) (27). A similar positive activity has been also reported 
when cetuximab is used in combination with carboplatin (28). 
Several mAbs have also been approved for the treatment of 
hematological malignancies. The most well known and widely 
used of these is rituximab, which is directed against the CD20 
receptor and has shown considerable success in patients with B 
cell non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic 
leukemia (29). A major advance in this field of anti-CD20 mAbs 
is the advent of glyco-engineered antibodies with higher avidity 
for the CD16 receptor that ignites ADCC on NK cells. In addi-
tion, antibody-conjugated drugs or toxins have been approved 
by FDA. These include brentuximab vedotin for patients with 
CD30-positive Hodgkin’s lymphoma (30), which provided the 
first proof-in-principle that antibodies can selectively deliver 
active drug to cancer cells.
Antibodies have also been devised to enhance cellular immune 
responses by activating or antagonizing immunological receptors 
important for the regulation of anti-cancer immunity. These are 
thus referred to as immunomodulatory or immunostimulatory 
mAbs. The concept behind the usage of the immunomodulatory 
mAbs is based on the knowledge that the immune system, and 
in particular T lymphocyte activity, is regulated by a balance of 
co-stimulatory and co-inhibitory signals known as immune check-
points. Under physiological conditions, these immune checkpoints 
are crucial to avoid autoimmunity and to protect bystander tissue 
during immune responses to infection. However, during cancer 
development, the balance conceivably shifts toward a reduced 
immune response, thereby resulting in unchecked tumor pro-
gression. The two molecules involved in the immune checkpoint 
regulation that have been most actively studied in the context of 
cancer immunotherapy are the CTLA-4 and PD-1 receptors. These 
are believed to inhibit immune responses at different levels and by 
different mechanisms (31).
The CTLA-4 receptor antagonizes binding between the TCR 
co-stimulatory molecule CD28 and the ligand CD86, thereby 
mediating a down modulation of T cell activation (32). An mAb 
able to functionally block CTLA-4 was made by Allison and 
colleagues who, in 1996, used a preclinical model to show that 
a significant antitumor response without overt immune toxicity 
was achieved when mice were treated with anti CTLA-4 antibody 
(33). These preclinical findings encouraged the production and 
testing of two fully humanized CTLA-4 antibodies, ipilimumab 
and tremelimumab, which began clinical trials in 2000. Both 
antibodies produced clinical response in patients with metastatic 
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melanoma. However, ipilimumab was more successful in 
development, being associated with a 17% ORR in patients with 
advanced melanoma (34, 35) and opening a window of hope for 
long-term survival in a percentage of these patients (36). These 
compelling evidences led to the FDA approval of ipilimumab for 
patients with advanced melanoma in 2010. Recently, to provide 
a more precise estimate of long-term survival observed for 
ipilimumab-treated patients with advanced melanoma, a pooled 
analysis of OS data from multiple studies was compiled. The 
analysis, performed on 1,861 patients with available follow-up 
of at least 3 years and up to 10 years, showed that after 3 years 
the survival reach a plateau with a rate survival equal to 20%. 
The plateau was independent of prior therapy or ipilimumab 
dose. These data supported the durability of long-term survival 
in ipilimumab-treated patients with advanced melanoma (37). 
The immunostimulatory mechanism of action of ipilimumab 
and the severe autoimmune phenotype of CTLA-4 knock-out 
mice suggested that immune-related adverse effects can occur. 
However, no correlation between efficacy and immune-related 
toxicity has been observed in ipilimumab-treated melanoma 
patients (38). Responses to ipilimumab have also been reported 
in patients with advanced uveal and mucosal melanoma, who 
generally have a poor prognosis and otherwise have limited 
treatment options (39, 40).
Following studies with antibodies direct against CTLA-4, gen-
erally considered the godfather of immune checkpoints, attention 
now is focused on the PD-1:PD-1 ligand (PD-L1) pathway. Under 
physiologic conditions, PD-1 interacts with PD-1 ligand 1 or 2 
(PD-L1 and PD-L2) to limit and regulate T cell activity in periph-
eral tissues during inflammatory or autoimmune processes. This 
co-inhibitory system has probably evolved to minimize collateral 
damage to healthy tissue and non-infected cells during clearance 
of intracellular viral orbacterial infections. Several mAb anti-PD-1 
and anti-PD-L1 mAb are now currently undergoing clinical trials 
with very successful and encouraging results.
In advanced melanoma, the anti-PD-1 drug pembrolizumab 
(formerly MK-3475) showed a high rate of sustained tumor 
regression with mainly grade 1 or 2 toxic effects in 135 patients, 
including some with previous disease progression on ipilimumab. 
Moreover, the response rate did not significantly differ between 
patients who had received prior ipilimumab treatment and 
those who had not (9). In September 2014, pembrolizumab 
(Keytruda) was the first approved anti-PD-1 drug by the FDA 
for the treatment of melanoma patients with relapsed or refrac-
tory disease. Pembrolizumab will be used in patients following 
treatment with ipilimumab, or after treatment with ipilimumab 
and a BRAF inhibitor in patients who carry mutated BRAF. A 
pivotal phase II study (KEYNOTE-002) has already shown that 
pembrolizumab improves the progression-free survival (PFS) 
compared to chemotherapy in patients with ipilimumab-refractory 
advanced melanoma (n = 540). At 6 months, the PFS rates for 
pembrolizumab-treated patients were more than 30% compared 
to 16% obtained with chemotherapy treatments (41). A study 
recently conducted on 834 patients with advance melanoma also 
showed that the usage of the anti-PD-1 antibody, pembrolizumab, 
prolonged PFS and OS and had less high-grade toxicity than did 
ipilimumab (42).
In parallel with pembrolizumab, other anti-PD-1 mAbs have 
been tested in clinical trials. Nivolumab, a fully human PD-1 block-
ing antibody, has been developed, and a durable clinical response 
(43, 44) together with increased survival has been reported in a 
large phase I trial recruiting patients with different tumor types, 
including melanoma, renal cell carcinoma, colorectal cancer, and 
non-small-cell lung cancer (NSCLC) (45). Significantly, increased 
survival was also observed by treating 418 previously untreated 
patients who had metastatic melanoma without a BRAF mutation 
with nivolumab versus dacarbazine. The results showed 72.9% 
overall rate of survival at 1 year in the nivolumab group compared 
with 42.1% in the dacarbazine group (46). A phase III study 
conducted also in melanoma also showed that nivolumab led to a 
greater proportion of patients achieving an objective response and 
fewer toxic effects than with alternative available chemotherapy 
regimens for patients with advanced melanoma that has progressed 
after ipilimumab or ipilimumab and a BRAF inhibitor (47). These 
encouraging results led to an accelerate approval in December 2014 
of nivolumab by FDA for the treatment of metastatic melanoma. In 
March 2015, nivolumab received also approval by the FDA for the 
second line of treatment of metastatic squamous NSCLC patients.
Potential predictive biomarkers for PD-1/PD-L1 targeting treat-
ment include PD-L1 expression by tumor cells by a variety of IHC 
techniques and laboratory assays. Some studies have suggested that 
the response to nivolumab might correlate with the expression of 
PD-L1 (48). Indeed, by performing preliminary analysis on 42 
patients with different cancer types before their treatment with 
nivolumab, it has been identified that PD-L1 expression on tumor 
cell surface as one factor associated with the clinical activity of 
anti-PD-1 therapy (43).
Despite these very encouraging results, the observation that 
a significant number of patients with PD-L1 positive expression 
(PD-L1+) tumors still do not respond to PD-1 pathway blockade 
(43) or still lack of increased OS compared to patients with negative 
PD-L1 expression (46) suggest that other factors might be needed to 
ensure an effective response to nivolumab therapy. Thus, additional 
studies might be necessary to select patients with increased likeli-
hood to respond to nivolumab and to other PD-1/PD-L1 targeting 
treatments and to possible co-target factors in combination treat-
ment regimens to ensure a more successful response.
On April 2015, nivolumab was approved from European 
Medicines Agency (EMA) for the treatment of advanced mela-
noma in first line. On May 2015, EMA approved nivolumab for 
the treatment of NSCLC in second line and pembrolizumab had 
the same indication of nivolumab in first line.
Cancer vaccines
Among the different immunotherapeutic strategies that have been 
introduced, cancer vaccination is the one most often investigated 
in a variety of preclinical and clinical settings (49). Since the first 
recognition of shared tumor-associated antigens in melanoma 
24 years ago (50), the appeal of potential vaccine that triggers spe-
cific antitumor immune response has led to considerable research 
in this area. However, most clinical trials have yielded disappointing 
results. In melanoma, the usage of gp100, a melanosomal protein, 
has been studied in several trials. The vaccination with an optimized 
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peptide derived from melanoma-associated antigen gp100 used in 
association with ipilimumab did not show any encouraging results 
compared with ipilimumab alone (36). However, gp100 vaccination 
applied concomitantly with IL-2 showed significantly improved 
PFS in a cohort of patients with metastatic melanoma (51). 
Another successful vaccine showing efficacy in large controlled 
phase III studies was sipuleucel-T, which consists of a preparation 
of autologous antigen-presenting cells activated and pulsed with 
a fusion protein consisting of prostatic acid phosphate (PAP) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). 
Treatment with sipuleucel-T in patients with metastatic prostate 
cancer improved median survival by approximately 4  months. 
Currently, sipuleucel-T is the only cancer vaccine approved by 
the FDA (52). This complex cell product, which involves three 
sequential leukapheresis leukocyte suspensions being cultured for 
48 h with the PAP–GM-CSF fusion protein, contains both antigen-
presenting cells and activated T cells and thus the exact mechanism 
of action is undefined. However, its use has been shown to prolong 
OS without improving PFS. A phase III trial utilizing this approach 
in melanoma yielded disappointing results (53).
In order to understand the problems associated with the lack of 
success of vaccine in cancer treatment, it is important to consider 
that the therapeutic vaccination against cancer is mostly based on 
the idea that there is a repertoire of functionally competent effector 
and memory T cells with specificity for tumor cell antigens at 
sufficient frequencies to control tumor progression (49). However, 
at least three major hurdles need to be considered. First, tumor 
antigens used in vaccination are self-proteins and T cells with 
high affinity receptors recognizing these antigens might have 
been deleted through thymic and peripheral negative selection. 
Second, tumors deploy panoply of molecules that are locally 
and systemically immunosuppressive, meaning mechanisms of 
immune tolerance against cancer-associated antigens need to 
be overcome. Lastly, tumor cells are notoriously heterogeneous 
and their antigen expression of a given tumor can range from 
completely negative to highly expressed changing also upon 
microenvironment and systemic conditions. Hence, it should be 
considered that cancer vaccines not only induce a newly primed 
T cell repertoire de novo but may also need to reactivate and 
potentially reeducate pre-existing tumor-reactive memory T cells. 
As such, the presence or absence of pre-existing effector/memory 
T cell responses represents an important prognostic biomarker for 
response to vaccination.
In addition, in order to have a successful vaccination, a high 
quality CD4 and CD8 effector and memory T cell responses against 
tumor-associated antigens need to be achieved.
Least but not last, the strength and type of the vaccine-induced 
immune response are truly determined by the amount of antigen 
presented by the activation/maturation of dendritic cells induced 
through the stimulation of danger-associated molecular pattern 
(DAMP) receptors (49).
A cumbersome but actively tested approach is to culture patients’ 
dendritic cells ex vivo, after loading their antigen-presentation 
pathways with sources of tumor antigens before being reinfused 
to the patient (54). Such complex and invividualized approach is 
difficult to test in large-scale randomized trials. However, the use of 
dendritic cells differentiated in culture with monocytes and loaded 
with whole cell tumor lysates is being tested in phase III trials in 
glioblastoma to prevent postsurgical relapse as well as in melanoma.
Nowadays, the emphasis of research is placed in vaccinating 
against the individual neoantigens of each malignancy. These are 
derived from the non-synonymous mutations encoded in the 
mutatome of each malignant disease case. A variety of research 
lines are suggesting the superiority of such individual antigens 
over shared antigens. However, the necessary biotechnology and 
bioinformatics for epitope prediction and individualized vaccine 
production are only at their infancy to consider wide scale deploy-
ment (55, 56). Poly-peptide and mRNA vaccines containing the 
mutations giving rise to HLA class I and II antigenic determinants 
are the most promising approaches.
In summary, despite mostly negative results, there is a continu-
ous interest in vaccine immunotherapy. The optimization and the 
refinement of existing and the development of novel vaccines, the 
identification of potential predictive biomarkers, and the combina-
tions with other forms of immunotherapy are goals that continue 
to be actively pursued.
Combinatorial immunotherapy
Optimizing immunotherapy can require treatments affecting 
multiple and combinatorial aspects of the immune response 
(57, 58). One immunotherapy combination consists of the use 
of cancer vaccines to generate anti-tumor T cells and immune 
checkpoints blockade to prevent T cell anergy. Survival studies 
performed in the B16 melanoma and CT26 colon carcinoma 
tumor models showed that the combination of PD-1 blockade with 
GM-CSF-secreting tumor cell immunotherapy leads to improved 
antitumor responses by augmenting the tumor-reactive T-cell 
responses induced by the cellular immunotherapy (59). In another 
preclinical study, the combination of CTLA-4 and PD-1 blockade 
was found more than twice as effective as either alone in promoting 
the rejection of B16 melanomas. The results suggested that the 
combination blockade of the PD-1/PD-L1- and CTLA-4-negative 
co-stimulatory pathways allowed tumor-specific T cells that would 
otherwise be inactivated to continue to expand and carry out 
effector functions, thereby shifting the tumor microenvironment 
from suppressive to inflammatory (60). Prompted by these stud-
ies, results of combinatorial immunotherapy have been reported 
also in humans. First, a small trial showed that periodic infusions 
of anti-CTLA-4 antibodies after vaccination with irradiated, 
autologous tumor cells engineered to secrete GM-CSF (GVAX) 
generated clinically meaningful antitumor immunity in a major-
ity of metastatic melanoma patients (61). Similarly, in a phase II 
trial, 245 patients with melanoma were randomized to receive 
ipilimumab and GM-CSF in combination or ipilimumab alone 
(60). The survival rate after 1 year of treatment in the combination 
arm was 68.9% compared with 52.9% in the monotherapy arm, 
while the median OS in the combination arm was 17.5 months 
compared with 12.7 months in the group of patients that received 
ipilimumab alone. Interestingly, GM-CSF mitigates the immune-
related adverse events of ipilimumab. Most excitingly, the combina-
tion of ipilimumab with bevacizumab (anti VEGF) in a phase I 
study of 22 melanoma patients has shown impressive results with 
1-year survival rate of 72% (53). Another promising combination 
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approach of bevacizumab plus MPDL3280A (an anti-PD-L1) is 
currently being evaluated (NCT01633970).
Encouraging evidences also derived from a study performed on 
86 patients with advanced melanoma treated with nivolumab and 
ipilimumab. The results showed that combinatorial therapy with 
nivolumab and ipilimumab induced a rapid and deep tumor regres-
sion in a substantial proportion of patients (62). Similar evidences 
have been also recently shown in a study involving 142 patients with 
metastatic melanoma who had not previously received treatment 
(63). The results demonstrated greater objective-response rate 
and PFS among patients treated with nivolumab combined with 
ipilimumab than with ipilimumab monotherapy. Taken altogether, 
these observations showed that the usage in combinations of immu-
nomodulatory approaches holds an absolutely unprecedented hope 
for a robust impact on the survival of cancer patients and may 
represent a decisive turning point for cancer therapy.
Conclusion
The immunotherapy field has exploded with the recent advances, 
especially in melanoma, demonstrating an improvement in survival 
and a durability of response. However, the perception is that this is 
not limited to any particular malignant disease but will be widely 
used across indications in oncology and hematology. The field is now 
investigating the role of novel approaches to be used either alone or 
in combination, such as (1) the blockade of lymphocyte activation 
gene 3 (LAG3), which normally stimulates Treg cells and inhibits 
CD8+ effector T cells through its interaction with MHC class II 
molecules and (2) T-cell membrane protein 3 (TIM3) antagonists, 
which have been shown to increase antitumor T cell responses when 
used in combination with anti-PD-1 agents. Immunostimulatory 
monoclonal antibodies that act as agonist of activatory receptors 
on immune system cells are also under fast clinical development 
(anti-OX40, anti-CD137, anti-CD27, anti-GITR, anti-CD40 mAbs).
Immunotherapy now offers treatments with the potential for 
long-term cure. Given these promising results and the large num-
ber of trials currently underway, it is very tempting to anticipate a 
bright future, especially for the treatment of advanced melanoma.
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